| Ytd | -43.23% | |
| 1y | -56.98% |
| Open | 6.83 | Prev Close | 6.86 | Low | 6.83 | High | 7.07 | Mkt Cap | 131.09M |
| Vol | 106.56K | Avg Vol | 407.57K | EPS | 1.09 | P/E | 6.41 | Forward P/E | 9.86 |
| Beta | 1.08 | Short Ratio | 2.70 | Inst. Own | 68.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.88 | 200-d Avg | 9.33 | 1yr Est | 10.36 |
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, veri
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressur
Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium poi
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as D
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despi
OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures
OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectation
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Conse
– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.
OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and acces
WALTHAM, Mass. , May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook,
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earn
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Wednesday's session saw 150 companies set new 52-week lows.
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn
Thursday's session saw 337 companies set new 52-week lows.
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings a
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to repor
On Friday, 1043 companies hit new 52-week lows.
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.